ПТ-141 (3мг х 10 Флаконы)

ПТ-141, также называется бремеланотид, is sometimes referred to as the female Viagra because the peptide was previously investigated in phase IIb human clinical trials for use in treating female hypoactive sexual desire disorder (HSDD). PT-141 is a melanocortin that binds primarily to melanocortin 4 рецептор (МС-4Р) и МС-1Р. В 2009, PT-141 was also investigated as a treatment for acute hemorrhage. PT-141 is a derivative of another synthetic melanocortin, меланотан 2 (МТ-2).

Последовательность: Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)
Молекулярная формула: С₅₀ЧАС₆₈Н₁₄О₁₀
Молекулярная масса: 1025.182 г/моль
ПабХим CID: 9941379
Количество CAS: 189691-06-3

PT-141 and Sexual Arousal

PT-141 — уникальный пептид, поскольку он стимулирует MC-4R., which is known to produce sexual arousal in the central nervous system and influence sexual behavior^{[1], [2]}. Studies in mice have shown that agonist binding to MC-4R causes sexual arousal and increased copulation in both males and females^{[3], [4]}. Because PT-141 works via a different mechanism than drugs like Viagra, it is possible to treat sexual arousal disorders in both men and women that stem from causes other than reduced blood flow to the genitals.

Исследование мужчин с эректильной дисфункцией (ЭД) кто не ответил на силденафил (Виагра) found that roughly one third experienced adequate erection for sexual intercourse with PT-141 (вводится через назальный спрей). There was also a strong dose-dependent response in the trial, indicating that PT-141 is indeed effective in certain cases^[]. This suggests that PT-141 could offer insight into correcting ED in settings where sildenafil has failed and may offer insight into central causes of hypoactive sexual desire.

интересно, PT-141 was pulled from clinical trials before it reached approval for use in women suffering from HSDD. This is despite signs that the drug increased the number of satisfying sexual events per month and decreased female sexual distress scores in a statistically significant manner without any substantial side effects^[6]. Many experts who treat female sexual dysfunction (ФСД) were dismayed to find the peptide was not being advanced despite positive results. They point to a lack of established endpoints for trials of FSD and socio-cultural biases against women’s sexual health as the primary roadblocks that are inhibiting approval of what they see as much-needed therapies^[7]. They hope that greater attention will be given to the topic and that the FDA will establish more concrete guidelines for evaluating therapies like PT-141 that can offer benefit. These experts also expressed dismay that the pharmacological treatments were not tested in conjunction with other established means of treating sexual dysfunction as they believe that the combination may prove synergistic and that peptides like PT-141 may be useful for overcoming initial barriers and jump-starting psychological treatment modalities.

В 2017, частично в ответ на протесты против прекращения предыдущих судебных процессов, Phase II Reconnect trials were launched using subcutaneous injections of PT-141 for FSD. The newest version of PT-141, называется Рекинда, may soon be available for use in the United States. It would be legal to use PT-141 off-label, в тот момент, to treat both male and female sexual dysfunction^[8]. These new trials have relied on the kind of modified endpoints that experts in FSD have touted as beneficial to seeing these kinds of treatments approved.

PT-141 и кровоизлияние

В 2009, PT-141 was modified slightly and investigated as a potential treatment for hemorrhagic shock. Поскольку PT-141 связывается как с MC-1R, так и с MC-4R., it reduces ischemia and protects tissues against inadequate blood supply in the setting of hypovolemic (геморрагический) шок. Препарат, при внутривенном введении, does not produce substantial side effects. It was last in phase IIb trials. The modified version of PT-141 is referred to as PL-6983.

PT-141 and Infection

MC-1R был найден., на крысиной модели специфической грибковой инфекции, to possess important anti-fungal and anti-inflammatory properties^[9]. This is of particular importance because current anti-fungals are limited in terms of their mechanism of action and all produce serious and treatment-limiting side effects in certain patients. Having an alternative to use in the treatment of fungal infections could reduce morbidity and mortality substantially, особенно у пациентов с ослабленным иммунитетом.

ПТ-141 и Рак

The MC-1R receptor is an important stimulus of DNA repair pathways and thus is of interest in cancer treatment and prevention^[10]. Research shows that people with variants of MC-1R are at increased risk for both basal cell and squamous cell carcinoma^[11]. Altered PT-141 may be able to correct the problems experienced as a result of these variants and prevent or treat these cancers.

Прямо сейчас, PT-141 has received widespread and intense attention as a treatment for sexual dysfunction. Есть, однако, a great deal of potential research outside of sexual dysfunction and hemorrhage that PT-141 could be applied to. Например, MC-4R is well-known to be defective or missing in certain cases of obesity and may account for as much as 6% всех случаев раннего ожирения. PT-141 offers a unique means of exploring this particular cause of obesity and potentially illustrating a pathway for intervention. MC-1R plays roles in both pain and inflammation as well as kidney pathology and the spread of infection. There is a plethora of available research that PT-141 could help to shed light on.

PT-141 имеет минимальные побочные эффекты., низкая биодоступность при пероральном приеме и отличная подкожная биодоступность у мышей. Дозировка на кг для мышей не масштабируется для людей.. PT-141 for sale at

Вышеуказанная литература была исследована, отредактировано и организовано доктором. Логан, доктор медицинских наук. Доктор. Логан получил докторскую степень в Медицинский факультет Университета Кейс Вестерн Резерв и степень бакалавра наук. в молекулярной биологии.

Доктор. Шерил А. Kingsberg is the chief of behavioral medicine at University Hospitals Case Medical Center and professor in Reproductive Biology and Psychiatry at Case Western Reserve University. Области ее клинической специализации включают сексуальную медицину., female sexual disorders, когнитивно-поведенческая психотерапия, менопауза, pregnancy and postpartum mood disorders, психологические аспекты бесплодия, and psychological and sexual aspects of cancer. Доктор. Kingsberg’s primary research interests are in treatments for female sexual disorders and the psychological aspects of infertility and menopause. She led a рандомизированный, плацебо-контролируемое исследование по подбору дозы for PT-141. She has numerous publications in many national and international journals, sits on the editorial board of Menopause and has authored numerous chapters on topics including perimenopause and sexuality, донорство ооцитов, бесплодие и старение, the treatment of psychogenic erectile dysfunction and sexuality after cancer. Доктор. Kingsberg received her PhD from the University of South Florida in Tampa and completed her fellowship in sexual medicine at University Hospitals Case Medical Center. She is an active member in a number of national and international organizations including the American Psychological Association and the American Society for Reproductive Medicine. She currently sits on the Board of Trustees of The North American Menopause Society, and serves as the current treasurer of the Society for Assisted Reproductive Technologies. Доктор. Kingsberg s a past president of The International Society for the Study of Women’s Sexual Health.

Доктор. Шерил А. Kingsberg is being referenced as one of the leading scientists involved in the research and development of PT-141. Ни в коем случае этот врач/ученый не одобряет и не пропагандирует покупку, распродажа, или использование этого продукта по любой причине. Нет никакой принадлежности или родства, подразумеваемый или иной, между

1. М. Sandrock, А. Schulz, С. Merkwitz, Т. Schöneberg, К. Spanel-Borowski, и А. Ricken, «Снижение количества желтых тел у мышей с ожирением и дефицитом рецептора меланокортина-4.,” Reprod. Биол. Эндокринол. ОБЭ, том. 7, п. 24, Мар. 2009.
2. р. С. Rosen, л. Э. Diamond, Д. С. Earle, А. М. Шадиак, и П. Б. Molinoff, “Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, агонист рецепторов меланокортина, in healthy male subjects and in patients with an inadequate response to Viagra,» Инт. Дж. Impot. Рез., том. 16, нет. 2, пп. 135–142, апрель. 2004. [ПабМед]
3. ЧАС. Уэсселс, В. Дж. Валовой, Дж. Хакетт, г. Он, п. Балсе-Сринивасан, и т. Вт. Vanderah, “Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection via brain and spinal melanocortin receptors,Нейронауки, том. 118, нет. 3, пп. 755–762, 2003. [ПабМед]
4. A.-S. Rössler, Дж. г. Пфаус, ЧАС. К. Ну давай же, Дж. Варнава, л. Alexandre, и Ф. Джулиано, «Агонист меланокортина, melanotan II, enhances proceptive sexual behaviors in the female rat,” Pharmacol. Биохимия. Поведение., том. 85, нет. 3, пп. 514–521, ноябрь. 2006. [ПабМед]
5. М. р. Safarinejad and S. Да. Хоссейни, “Salvage of sildenafil failures with bremelanotide: рандомизированный, двойной слепой, плацебо-контролируемое исследование,» Дж.. Урол., том. 179, нет. 3, пп. 1066–1071, Мар. 2008. [ПабМед]
6. А. ЧАС. Клейтон и др., “Bremelanotide for female sexual dysfunctions in premenopausal women: рандомизированный, плацебо-контролируемое исследование по подбору дозы,” Womens Health Lond. англ., том. 12, нет. 3, пп. 325–337, 2016. [ПабМед]
7. М. К. Миллер, Дж. р. Смит, Дж. Дж. Норман, и А. ЧАС. Клейтон, “Expert opinion on existing and developing drugs to treat female sexual dysfunction,Экспертное мнение. Emerg. Наркотики, том. 23, нет. 3, пп. 223–230, 2018. [ПабМед]
8. “AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to RekyndaTM (бремеланотид), a Potential Treatment for a Common Female Sexual Disorder – AMAG Pharmaceuticals.” . [Обзор рынка]
9. ЧАС. Джи и др., «Синтетический меланокортин (ЦКПВ)2 Exerts Anti-Fungal and Anti-Inflammatory Effects against Candida albicans Vaginitis via Inducing Macrophage M2 Polarization,ПЛОС ОДИН, том. 8, нет. 2, февраль. 2013. [ПЛОС ОДИН]
10. В. Мареска, Э. ФЛОРА, И м. Пикардо, «Фототип кожи: новая перспектива,” Pigment Cell Melanoma Res., том. 28, нет. 4, пп. 378–389, июль. 2015. [ПабМед]
11. л. Феллер, р. а. г. В Кхамми, Б. Крамер, М. Альтини, и Дж.. Конечности, “Basal cell carcinoma, плоскоклеточный рак и меланома головы и лица,” Head Face Med., том. 12, п. 11, февраль. 2016. [ПабМед]
12. Клейтон АХ, Альтхоф SE, Кингсберг С, и другие. Bremelanotide for female sexual dysfunctions in premenopausal women: рандомизированный, плацебо-контролируемое исследование по подбору дозы. Womens Health (Лондон). 2016;12(3):325–337. дои:10.2217/WH-2016-0018
13. Т. р. McMillan, М. А. М. Форстер, л. я. Короткий, А. п. Рудецкий, Д. л. Клайн, и С. л. Gray, “Melanotan II, агонист меланокортина, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice,Опыт. Физиол. , том. 106, нет. 2, пп. 427–437, февраль. 2021, дои: 10.1113/EP088838.”
14. С. Скаут, р. Иордания, и С. Фишкофф, “Effect of bremelanotide on body weight of obese women: Данные двухфазного 1 рандомизированные контролируемые исследования,Диабет, ожирение. Метаб., том. 24, нет. 6, пп. 1084–1093, июнь. 2022, дои: 10.1111/дом.14672. »

ВСЕ СТАТЬИ И ИНФОРМАЦИЯ О ПРОДУКЦИИ, ПРЕДОСТАВЛЕННЫЕ НА ЭТОМ ВЕБ-САЙТЕ, ПРЕДНАЗНАЧЕНЫ ТОЛЬКО ДЛЯ ИНФОРМАЦИОННЫХ И ОБРАЗОВАТЕЛЬНЫХ ЦЕЛЕЙ..

Продукты, предлагаемые на этом сайте, предназначены только для исследований in vitro.. Исследования in vitro (латинский: в стекле) выполняются вне тела. Эти продукты не являются лекарствами или лекарствами и не были одобрены FDA для предотвращения, лечить или вылечить любое заболевание, недуг или болезнь. Телесное введение любого вида в организм человека или животного строго запрещено законом..